Eliem Therapeutics Total Long-Term Assets 2021-2024 | CLYM
Eliem Therapeutics total long-term assets from 2021 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
Eliem Therapeutics Annual Total Long-Term Assets
(Millions of US $) |
| 2023 |
$0 |
| 2022 |
$1 |
| 2021 |
$25 |
| 2020 |
$3 |
Eliem Therapeutics Quarterly Total Long-Term Assets
(Millions of US $) |
| 2024-06-30 |
$0 |
| 2024-03-31 |
$0 |
| 2023-12-31 |
$0 |
| 2023-09-30 |
$0 |
| 2023-06-30 |
$2 |
| 2023-03-31 |
$2 |
| 2022-12-31 |
$1 |
| 2022-09-30 |
$8 |
| 2022-06-30 |
$17 |
| 2022-03-31 |
$29 |
| 2021-12-31 |
$25 |
| 2021-09-30 |
$24 |
| 2021-06-30 |
$3 |
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
